Shares of Agile Therapeutics Inc (NASDAQ:AGRX) saw unusually-strong trading volume on Tuesday . Approximately 1,728,847 shares traded hands during mid-day trading, an increase of 72% from the previous session’s volume of 1,006,132 shares.The stock last traded at $0.79 and had previously closed at $0.46.
Separately, ValuEngine cut shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 2nd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $4.00.
The stock has a market capitalization of $12.60 million, a price-to-earnings ratio of -1.00 and a beta of 1.43.
Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. Analysts expect that Agile Therapeutics Inc will post -0.61 earnings per share for the current year.
In related news, insider Life Sciences Maste Perceptive sold 298,628 shares of the business’s stock in a transaction on Thursday, July 26th. The shares were sold at an average price of $0.30, for a total value of $89,588.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.30% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. A.R.T. Advisors LLC grew its holdings in Agile Therapeutics by 82.3% in the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after purchasing an additional 29,995 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after purchasing an additional 343,290 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Agile Therapeutics by 17.0% in the first quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after purchasing an additional 487,400 shares during the last quarter. 52.00% of the stock is currently owned by institutional investors and hedge funds.
About Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Recommended Story: Ex-Dividend